HTBX - Heat Biologics, Inc.
| Previous Close | 0.6300 |
| Open | 0.6331 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.6230 - 0.6700 |
| 52 Week Range | 0.4600 - 3.3500 |
| Volume | 142,248 |
| Avg. Volume | 414,492 |
| Market Cap | 23.25M |
| Beta | 0.62 |
| PE Ratio (TTM) | -1.50 |
| EPS (TTM) | -0.43 |
| Earnings Date | Oct 30, 2017 - Nov 3, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.63 |
- ACCESSWIRE•7 days ago
Heat Biologics Announces Pricing for Rights Offering to Stockholders and Participating Warrant Holders
DURHAM, NC / ACCESSWIRE / October 16, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against ...
- ACCESSWIRE•11 days ago
UPDATE: Heat Biologics to Present at the Upcoming BIO Investor Forum in San Francisco
DURHAM, NC / ACCESSWIRE / October 12, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system ...
- Simply Wall St.•12 days ago
Before You Buy Heat Biologics Inc’s (HTBX), You Should Consider This
For Heat Biologics Inc’s (NASDAQ:HTBX) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. HTBX is exposedRead More...
- Business Wire•19 days ago
Selexis SA and Pelican Therapeutics Sign Agreement to Advance Pelican’s Immunotherapy Clinical Programs
Selexis SA and Pelican Therapeutics , a subsidiary of Heat Biologics, Inc. , announced that they have entered into a service agreement to advance the development of Pelican’s proprietary immunotherapy clinical candidates.
- ACCESSWIRE•25 days ago
Heat Biologics Announces Expected Calendar for Rights Offering
DURHAM, NC / ACCESSWIRE / September 28, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against ...
- ACCESSWIRE•26 days ago
Pelican Therapeutics Announces Manufacturing Agreement with KBI Biopharma to Advance Cancer-targeting Immunotherapies
DURHAM, NC / ACCESSWIRE / September 27, 2017 / Pelican Therapeutics ("Pelican"), a subsidiary of Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), entered into a manufacturing agreement ...
- ACCESSWIRE•last month
Heat Biologics Announces Common Stock Rights Offering in Form S-1 Filing
DURHAM, NC / ACCESSWIRE / September 15, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against ...
- ACCESSWIRE•last month
Heat Biologics Granted 180-day Extension by NASDAQ to Regain Compliance with Listing Requirements
DURHAM, NC / ACCESSWIRE / September 14, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against ...
- ACCESSWIRE•last month
Today's Research Reports on Stocks to Watch: Advaxis and Heat Biologics
NEW YORK, NY / ACCESSWIRE / September 13, 2017 / Heat Biologics saw a gain on Tuesday after announcing that it has been granted a Type C FDA meeting to discuss its non-small cell lung cancer (NSCLC) trial ...
- ACCESSWIRE•last month
Heat Biologics Granted Type C Meeting with FDA to Discuss Registrational Pathway for HS-110 in Combination with Opdivo(R) as a Treatment for Non-Small Cell Lung Cancer
DURHAM, NC / ACCESSWIRE / September 12, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against ...
- ACCESSWIRE•2 months ago
Heat Biologics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York
DURHAM, NC / ACCESSWIRE / September 7, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system ...
- ACCESSWIRE•2 months ago
Heat Biologics Inc. Reports Second Quarter 2017 Results
DURHAM, NC / ACCESSWIRE / August 14, 2017 / Heat Biologics , Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company focused on developing immuno-oncology therapies to activate a patient's ...
- Accesswire•4 months ago
Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics
DURHAM, NC / ACCESSWIRE / July 3, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, ...
- Accesswire•4 months ago
Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics
DURHAM, NC / ACCESSWIRE / July 3, 2017 / Heat Biologics, Inc. ("Heat") (Nasdaq: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, ...
- Accesswire•4 months ago
Heat Biologics Appoints Damien Hallet as Vice President of CMC Development
DURHAM, NC / ACCESSWIRE / July 3, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, ...
- Accesswire•4 months ago
Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives First Tranche of $15.2 Million CPRIT Grant Award
DURHAM, NC / ACCESSWIRE / June 28, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, ...
- Accesswire•4 months ago
Heat Biologics to Present at the 2017 BIO International Convention
DURHAM, NC / ACCESSWIRE / June 12, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, ...
- Accesswire•5 months ago
Heat Biologics to Present at the 2017 Marcum Microcap Conference
DURHAM, NC / ACCESSWIRE / June 7, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, ...
- Accesswire•5 months ago
Heat Biologics Presents Poster on its Phase 2 Trial Evaluating HS-410 at ASCO Annual Meeting
Data reinforces clinical and immune response correlation DURHAM, NC / ACCESSWIRE / June 5, 2017 / Heat Biologics, Inc. ("Heat") (Nasdaq: HTBX), a leader in the development of novel therapies ...
- Accesswire•5 months ago
Heat Biologics to Present Poster at 2017 ASCO Annual Meeting
DURHAM, NC / ACCESSWIRE / May 30, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, ...
- Accesswire•5 months ago
Heat Biologics Provides Business and Clinical Update for the First Quarter of 2017
Heat to Double-Down on Checkpoint Combination Therapies Based on Positive Interim Data of HS-110+PD-1 Checkpoint in Lung Cancer; Acquires Pelican Therapeutics Which Brings with it a $15.2 Million CPRIT ...
- Accesswire•6 months ago
Heat Biologics Announces Completion of Acquisition of Pelican Therapeutics
Acquisition Brings $15.2 Million CPRIT Grant to Fund 70-Patient Phase 1 Trial DURHAM, NC / ACCESSWIRE / May 1, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a leader in the development ...
